Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
ATLANTA, Jan. 29, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET to review the Company’s financial results for the three month period ended December 31, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 31712361. The live webcast can be accessed under the Investors section of the Company’s website at www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/pa9bmsp5.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Contact: Mark Colonnese Executive Vice President and Chief Financial Officer Biota Pharmaceuticals, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
